Zahi A Fayad, PhD
- DIRECTOR, BIOMEDICAL ENGINEERING AND IMAGING INSTITUTE
- PROFESSOR | Diagnostic, Molecular and Interventional Radiology
- PROFESSOR | Medicine, Cardiology
Research Topics:Atherosclerosis, Cardiovascular, Computed Tomography, Image Analysis, Imaging, Magnetic Resonance Imaging, Nanotechnology
Dr. Fayad serves as professor of Radiology and Medicine (Cardiology) at the Icahn School of Medicine at Mount Sinai and holds the Lucy G. Moses Professorship in Medical Imaging and Bioengineering. He is the founding Director of the Biomedical Engineering and Imaging Institute; Vice chair for Research, Department of Radiology at the Icahn School of Medicine at Mount Sinai. Dr. Fayad’s interdisciplinary and discipline bridging research - from engineering to biology and from pre-clinical to clinical investigations - has been dedicated to the detection and prevention of cardiovascular disease with many seminal contributions in the field of multimodality biomedical imaging (MR, CT, PET and PET/MR) and nanomedicine. His work has recently expanded in understanding the effect of stress on the immune system and cardiovascular disease. He has authored more than 300 peer-reviewed publications (h-index of 71 accessed 01/02/2017 on Thomson Reuters Web of Science), 50 book chapters, and over 500 meeting presentations. He is currently the Principal Investigator (PI) of 5 federal grants (4 R01s and 1 P01) funded by the National Institutes of Health’s National Heart, Lung and Blood Institute and National institute of Biomedical Imaging and Bioengineering. He is also PI on three NIH sub-contracts with UCSD, Columbia and the Brigham and Women’s Hospital. In addition, he serves as Principal Investigator of the Imaging Core of the Mount Sinai National Institute of Health (NIH)/Clinical and Translational Science Awards (CTSA). He is a PI of one of the 3 projects in the Strategically Focused Prevention Research Network Center grant funded by the American Heart Association (AHA) to promote cardiovascular health among high-risk New York City children, and their parents, living in Harlem and the Bronx. Moreover, he currently leads four pharmaceutically funded multicenter clinical trials for the evaluation of novel cardiovascular drugs. He is Associate Editor for the Journal of the American College of Cardiology Imaging (JACC Imaging), Section Editor for Journal of the American College of Cardiology (JACC) and Consulting Editor for Arteriosclerosis Thrombosis and Vascular Biology (ATVB) and past associate Editor of Magnetic Resonance in Medicine (MRM). In 2013, he became a Charter Member, NIH Center of Scientific Review, Clinical Molecular Imaging and Probe Development Study Section. In 2015, he chaired the Scientific Advisory Board of the Institut National de la Santé et de la Recherche Médicale (INSERM) PARCC program at the HEGP in Paris. Dr. Fayad had his engineering trainings at Bradley University (BS, Electrical Engineering ’89), the Johns Hopkins University (MS, Biomedical Engineering ‘91) and at the University of Pennsylvania (PhD. Bioengineering ’96). From 1996 to 1997 he was junior faculty in the Department of Radiology at the University of Pennsylvania. In 1997 he joined the faculty at Mount Sinai School ofMedicine. Dr. Fayad is the recipient of multiple prestigious awards. In 2007 he was given the John Paul II Medal from Krakow, Poland in recognition for the potential of his work on humankind. As a teacher and mentor, Dr. Fayad has been also extremely successful. He has trained over 100 postdoctoral fellows, clinical fellows and students. His trainees have received major awards, fellowships, and positions in academia and industry. In 2008, he received the Outstanding Teacher Award from the International Society of Magnetic Resonance in Medicine (ISMRM) for his teaching on cardiovascular imaging and molecular imaging. In 2009 he was awarded the title of Honorary Professor in Nanomedicine at Aarhus University in Denmark. Recently, he was one of opening speakers at the 2011 97th Scientific Assembly and Scientific meeting of the Radiological Society of North America (RSNA). In 2012, he was invited to give the Henry I Russek Lecture at the 45th Anniversary of the ACCF New York Cardiovascular Symposium. In 2013, he was elected Fellow of the International Society of Magnetic Resonance In Medicine, Magnetic Resonance Imaging, received a Distinguished Reviewer from Magnetic Resonance in Medicine and was selected as an Academy of Radiology Research, Distinguished Investigator In 2014 he received the Centurion Society award from his alma matter (highest award) Bradley University for his bringing national and international credit to his alma matter. In 2014, he received the Editor’s Recognition Award, from the Journal Radiology. In 2015, he was the Dr. Joseph Dvorkin Memorial Lecturer at the Cardiac Research Day of the Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, Canada. In 2016, he was the Heart & Stroke/Richard Lewar lecturer at the Center of Excellence in Cardiovascular Research in Toronto. He is married to Monique P. Fayad, MBA and is the proud father of Chloé (15 year old) and Christophe (10 year old) and after spending seven years in Manhattan now lives in Larchmont, runs in Central Park and participates regularly in New York Road Runners races. He also enjoys regular sailing and stand-up board paddling in Larchmont, New York, Connecticut, Rhode Island, Cape Cod, Martha’s Vineyard, Nantucket, the Caribbean Islands and beyond. He also practices all type of daily fitness regimens that include strength, cardiovascular, core, flexibility and high intensity interval trainings for fun.
Multi-Disciplinary Training AreasArtificial Intelligence and Emerging Technologies in Medicine [AIET], Pharmacology and Therapeutics Discovery [PTD]
BSEE, Bradley University
MSE, Johns Hopkins University
PhD, University of Pennsylvania
Opening Session Distinguished Lecturer
My laboratory is focused on developing and using noninvasive imaging methods that allow the early detection, prevention, and treatment of cardiovascular disease. Despite considerable therapeutic advances over the past 50 years, cardiovascular disease is the leading cause of death worldwide. This is mainly a result of the increasing prevalence of atherosclerosis, owing to the ageing population, the improved survival of patients with atherosclerotic cardiovascular disease and, above all, the widespread under-recognition and undertreatment of individuals with risk factors for atherosclerosis. Atherosclerosis is characterized by the thickening of the arterial wall to form an atherosclerotic plaque, a process in which cholesterol deposition, inflammation, extracellular-matrix formation and thrombosis have important roles (see Sanz and Fayad Nature 2008; 45:953-957). Symptoms occur late in the course of disease and are usually caused by the narrowing of the lumen of the artery, which can happen gradually (as a result of progressive plaque growth) or suddenly (as a result of plaque rupture and, subsequently, thrombosis). The resultant decrease in blood supply can affect almost any organ, although coronary heart disease and stroke are the most common consequences.
Traditionally, diagnosis of atherosclerosis was possible only at advanced stages of disease, either by directly revealing the narrowing of the arterial lumen (stenosis) or by evaluating the effect of arterial stenosis on organ perfusion. We are developing and using, new imaging approaches that allow the assessment not only of the morphology of blood vessels but also of the composition of the vessel walls, enabling atherosclerosis-associated abnormalities in the arteries (including the coronary arteries) to be observed, down to the cellular and molecular level in some cases. Some of these approaches are now in clinical use or are being tested in clinical trials, whereas others are better suited to basic (preclinical) and translational research.
Our current activities are focused on:
Imaging Acquisition and Analysis Methods: Development of novel multimodality cardiovascular imaging and analysis techniques using macro- and micro- Cardiovascular Magnetic Resonance (CMR), computed tomography (CT), positron emission tomography (PET), and optical imaging.
Early Detection and Outcomes Prediction: Use of in vivo noninvasive multimodality imaging methods for the early detection of atherosclerosis in humans and for cardiovascular events and outcomes prediction.
Clinical Trials and Drug Development: Use in vivo noninvasive multimodality imaging methods in clinical trials for the development and testing of novel therapeutics to treat atherosclerosis.
Molecular Imaging: Development and use of novel multimodality imaging nanoparticulate systems to monitor fundamental cellular/molecular events in living subjects including patients.
Drug Delivery: Development and use of novel targeted drug delivery nanoparticulate systems to improve the treatment of atherosclerosis in living subjects including patients.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Fayad during 2022 and/or 2023. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
- Trained Therapeutics Discovery
Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)
- Trained Therapeutics Discovery
- Trained Therapeutics Dis; Trained Therapeutics Discovery; Trained Therapeutucs Discovery
Scientific Advisory Board:
- Trained Therapeutics Discovery
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.